title: Choroidal neovascularization in acquired partial lipodystrophy.
abstract: OBJECTIVE
  To report a case of choroidal neovascularization (CNV) associated with acquired partial lipodystrophy (PLD).
  
  
  METHODS
  A 55-year-old woman with a known history of PLD presented with acute onset visual loss affecting her right eye and underwent investigations to diagnose the underlying pathology.
  
  
  RESULTS
  Fluorescein angiography and time-domain optical coherence tomography demonstrated the presence of intraretinal edema consistent with CNV. The patient was treated with intravitreal ranibizumab with excellent results, and her vision remains unimpaired 4 years posttreatment.
  
  
  CONCLUSIONS
  Choroidal neovascularization is an angiogenic process that can occur following retinal pigment epithelium disruption of any cause. These vessels may then bleed into retinal tissue, with potentially devastating visual consequences. Although rare, PLD has been associated with retinal drusenoid lesions. This is the first case to report CNV in association with PLD, and highlights the importance of considering CNV in the differential diagnosis of acute visual loss in patients with drusenoid diseases such as PLD.
authors.affiliation: University of Sydney, Sydney and Sydney Retina Clinic & Day Surgery, 187 Macquarie Street, Sydney, NSW 2000, Australia. gbro8081@uni.sydney.edu.au
authors.forename: Geoffrey K
authors.initials: GK
authors.lastname: Broadhead
authors.forename: Andrew
authors.initials: A
authors.lastname: Chang
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D052496:Lipodystrophy, Familial Partial / Q000150:complications* / Q000175:diagnosis; D008875:Middle Aged; D010211:Papilledema / Q000175:diagnosis / Q000209:etiology; D000069579:Ranibizumab; D041623:Tomography, Optical Coherence; D014786:Vision Disorders / Q000209:etiology; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab